Canada's Profound Medical Q3 revenue slightly misses estimates
Canada's Profound Medical Q3 revenue slightly misses estimates
Overview
Canada medical device maker's Q3 revenue rose 86% yr/yr, slightly missing analyst expectations
Gross margin rose to 78% from 74% a year earlier
Company projects 2026 revenue of at least $25 mln and gross margin of 70% or higher
Outlook
Profound expects 2026 revenue of at least $25.0 mln
Company projects 2026 gross margin of 70% or higher
Profound expects cash and revenue to cover operating needs for at least 12 months
Result Drivers
RECURRING REVENUE AND SYSTEM SALES - Co said Q3 revenue growth was driven by higher capital equipment sales and recurring revenue from single-use devices and services
GROSS MARGIN EXPANSION - Gross margin rose due to favorable product mix and price discipline
PAYER COVERAGE - Co said expanded commercial and government payer coverage supported adoption of TULSA Procedure
Company press release: ID:nGNXc4WN78
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Miss* | $9.8 mln | $9.87 mln (3 Analysts) |
Q3 Loss Per Share |
| $0.21 |
|
Q3 Net Loss |
| $7.7 mln |
|
Q3 Operating Expenses |
| $15.5 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Reuters Recommended Reads
Nov 3 - Sofwave Medical Q3 revenue rises 35% on usage fees
Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices
Nov 2 - SI-BONE Q3 revenue rises 14.5%, slightly beats estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)